AbbVie, Immunome sign deal valued at $2.8B
2023-01-10
AbbVie will pay $30 million in cash upfront as part of an oncology deal with Immunome to select up to 10 novel target-antibody pairs with an option to acquire global rights for these target-antibody pairs associated with three specific tumor types. The deal, valued at up to $2.8 billion, covers platform access payments worth up to $70 million, up to $120 million in development and commercial milestones per target, and potential additional sales of up to $150 million for each target in addition to royalties.
Full story: 
AIChE SmartBrief
Chemical engineering news
Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly email newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.